1.55
-0.07 (-4.04%)
| Penutupan Terdahulu | 1.61 |
| Buka | 1.54 |
| Jumlah Dagangan | 149,603 |
| Purata Dagangan (3B) | 355,076 |
| Modal Pasaran | 42,649,568 |
| Harga / Jualan (P/S) | 0.460 |
| Harga / Buku (P/B) | 2.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2025 - 19 May 2025 |
| Margin Keuntungan | -59.52% |
| Margin Operasi (TTM) | -151.04% |
| EPS Cair (TTM) | -2.96 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -7.10% |
| Nisbah Semasa (MRQ) | 1.23 |
| Aliran Tunai Operasi (OCF TTM) | -102.22 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.57 M |
| Pulangan Atas Aset (ROA TTM) | -38.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,739.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Fortress Biotech, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.30 |
|
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 27.70% |
| % Dimiliki oleh Institusi | 17.36% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Kestra Advisory Services, Llc | 31 Dec 2024 | 226,231 |
| Julat 52 Minggu | ||
| Median | 16.00 (935.60%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Roth MKM | 11 Mar 2025 | 16.00 (935.60%) | Beli | 1.73 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JIN DAVID | 1.54 | - | 5,000 | 7,700 |
| Jumlah Keseluruhan Kuantiti Bersih | 5,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 7,700 | |||
| Purata Pembelian Keseluruhan ($) | 1.54 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| JIN DAVID | Pegawai | 01 Apr 2025 | Diperolehi (+) | 5,000 | 1.54 | 7,700 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |